Taysha Gene Therapies, Inc. Stock price

Equities

TSHA

US8776191061

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
2.87 USD -9.46% Intraday chart for Taysha Gene Therapies, Inc. -7.42% +62.15%
Sales 2024 * 6.75M Sales 2025 * 5.09M Capitalization 537M
Net income 2024 * -76M Net income 2025 * -91M EV / Sales 2024 * 67.6 x
Net cash position 2024 * 80.09M Net cash position 2025 * 114M EV / Sales 2025 * 83 x
P/E ratio 2024 *
-7.13 x
P/E ratio 2025 *
-5.98 x
Employees 52
Yield 2024 *
-
Yield 2025 *
-
Free-Float 75.2%
More Fundamentals * Assessed data
Dynamic Chart
Chardan Adjusts PT on Taysha Gene Therapies to $7 From $5 as Gene Therapy for Rett Syndrome Shows 'Sustained Benefit', Keeps Buy Rating MT
Wall Street Set to Open Flat as Investors Look Toward Fed Decision; Oil Prices Drop Sharply MT
US Futures Flat in Wednesday's Premarket as Investors Await Fed's Interest Rate Decision MT
Top Premarket Gainers MT
Needham Adjusts Taysha Gene Therapies Price Target to $7 From $5, Maintains Buy Rating MT
Taysha Gene Therapies Surges 26% Premarket After Full-Year 2023 Results Show Narrowing Net Loss, Surging Revenue MT
North American Morning Briefing : Markets on Hold as Fed Decision Nears DJ
Transcript : Taysha Gene Therapies, Inc., 2023 Earnings Call, Mar 19, 2024
Taysha Gene Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Taysha Gene Therapies, Inc. Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome CI
Taysha Gene Therapies, Inc.(NasdaqGS:TSHA) added to NASDAQ Biotechnology Index CI
Taysha Gene Therapies Gets Expanded Eligibility in Canada for Early Trial of Rett Syndrome Treatment MT
Taysha Gene Therapies, Inc. Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients CI
Taysha Gene Therapies Insider Bought Shares Worth $163,000, According to a Recent SEC Filing MT
Cantor Fitzgerald Adjusts Price Target on Taysha Gene Therapies to $7 From $6, Keeps Overweight Rating MT
More news

Latest transcript on Taysha Gene Therapies, Inc.

1 day-9.46%
1 week-7.42%
Current month-9.18%
1 month+8.71%
3 months+61.24%
6 months-5.28%
Current year+62.15%
More quotes
1 week
2.86
Extreme 2.86
3.43
1 month
2.06
Extreme 2.06
3.55
Current year
1.38
Extreme 1.38
3.55
1 year
0.50
Extreme 0.5
3.89
3 years
0.50
Extreme 0.5
27.00
5 years
0.50
Extreme 0.5
33.35
10 years
0.50
Extreme 0.5
33.35
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 20-02-29
Director of Finance/CFO 46 20-07-31
President 58 20-06-30
Members of the board TitleAgeSince
Director/Board Member 63 20-08-30
Chief Executive Officer 56 20-02-29
Director/Board Member 54 23-06-20
More insiders
Date Price Change Volume
24-03-28 2.87 -9.46% 4,211,874
24-03-27 3.17 +3.59% 2,503,124
24-03-26 3.06 0.00% 2,145,239
24-03-25 3.06 -5.85% 3,243,077
24-03-22 3.25 +4.84% 3,066,651

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). It received orphan drug designation from the European Commission for TSHA-120 for the treatment of GAN.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
2.87 USD
Average target price
6.056 USD
Spread / Average Target
+111.00%
Consensus
  1. Stock
  2. Equities
  3. Stock Taysha Gene Therapies, Inc. - Nasdaq